Endeavor DES status
This article was originally published in The Gray Sheet
Executive Summary
Medtronic plans to hold discussions with FDA this month to identify further IDE requirements for its 480-patient, ENDEAVOR III clinical study assessing the paclitaxel-eluting stent. Under conditional IDE clearance, announced Dec. 24, Medtronic may begin a limited registry at selected sites. ENDEAVOR III will randomize patients to Endeavor or Johnson & Johnson/Cordis' sirolimus-eluting Cypher...